Novo Nordisk's Obesity Franchise Expands Reach as Comorbidity Data and Pipeline Catalysts Converge

Semaglutide reduces asthma exacerbations by 26% and migraine medication use by 7%. Stock rebounds 13% in 30 days; CagriSema FDA decision expected Q4 2026.

Novo Nordisk is making a case that its blockbuster GLP-1 drugs can do more than shrink waistlines. Fresh evidence presented at the European Congress on Obesity (ECO) in Istanbul suggests semaglutide — the active ingredient in Wegovy and Ozempic — cuts asthma exacerbations by 26% and reduces reliance on emergency inhalers by 14%, based on an analysis of 27,523 patients already taking GLP-1 medications alongside standard asthma therapy. The company has also flagged Danish registry data covering 150,000 Wegovy users from 2022 to 2024 showing that women prescribed the drug filled 7% fewer triptan scripts for migraine a year after starting treatment. Both datasets point to a potential anti-inflammatory benefit that could reposition Wegovy from a pure weight-loss agent into a broader metabolic and chronic-disease therapy.

Those observations arrive at a time when Novo Nordisk's financial performance is under pressure but not in freefall. The stock closed at €39.27 on Thursday, up 13.79% over the past 30 days but still down 33.72% over the past 12 months. The 200-day moving average sits at €42.41, underscoring that the recent bounce has yet to reclaim the old trend. In the secondary article's price reference, the shares traded at €40.02 — essentially flat day-on-day — with a 30-day gain of 19.57% and a year-to-date deficit of 10.42%. The gap between the two quotes reflects a single session's drift, but the message is consistent: Novo Nordisk is clawing back losses even as the broader narrative remains cautious.

The company's first-quarter update released in May confirmed that headwinds persist. Adjusted revenue fell 10% to 70.1 billion Danish kroner, while adjusted earnings per share dropped 3%. CEO Mike Doustdar highlighted that the oral formulation of Wegovy, launched at the start of 2026, has already been taken by more than one million patients — a brisk uptake that helped lift 2026 full-year guidance. Novo Nordisk now expects currency-adjusted revenue and operating profit to decline by 4% to 12%, a softer landing than the market had feared. In the critical U.S. market, Wegovy accounts for 65% of all new prescriptions, and the company maintains a 55% share of weekly injectable GLP-1 products despite Eli Lilly's aggressive push.

The real hinge for the stock, however, is the pipeline — specifically CagriSema, a dual GLP-1/amylin analogue that Novo Nordisk has filed for U.S. approval. In the REDEFINE 1 trial, CagriSema delivered a mean weight loss of 22.7% after 68 weeks, versus 16.1% for semaglutide alone. The combination beat both components handily, though earlier readouts had disappointed because the effect fell short of Eli Lilly's Zepbound. The U.S. Food and Drug Administration is expected to rule on the application in the fourth quarter of 2026, and a parallel cardiovascular outcomes study, REDEFINE 3, is enrolling 7,000 patients to assess long-term safety and benefit.

Meanwhile, Novos other metabolic candidates — including Amycretin and UBT251, which mimic multiple gut hormones — are advancing through early-stage trials. The company also reported six regulatory approvals and more than ten new study starts in the first quarter alone. Research, development and marketing costs came in at 22.4 billion Danish kroner for the quarter, and a share buyback program of up to 15 billion kroner is running through 2026.

Beyond the pipeline, recent data from the RESETTLE study at the University of Copenhagen and Holbæk Hospital targets a notoriously difficult patient segment: young adults aged 18 to 28 with severe obesity who had previously responded poorly to pediatric interventions. After 68 weeks on a weekly 2.4-milligram dose of semaglutide, they recorded a 19% drop in BMI, an average weight loss of 22.3 kilograms, a 48% reduction in belly fat and a 39% reduction in liver fat. Gastrointestinal side effects occurred but were manageable within the study protocol.

On the regulatory front, the FDA issued a warning concerning Novo Nordisk's Plainsboro, New Jersey facility over delayed reporting of serious adverse events across several products, including semaglutide. The company stressed that the agency did not raise new safety concerns about the medicines themselves. In parallel, Novo Nordisk paid Omeros $240 million upfront for rights to Zaltenibart, a deal that could total up to $2.1 billion and targets immunology and rare diseases.

With the stock trading at 13.6 times forward earnings — a discount to the healthcare sector average of 16.8 times — much skepticism is already priced in. The global obesity market counts more than 900 million people, yet only about 1% currently receive branded medications. For Novo Nordisk, the next concrete catalyst comes in Q4 2026 with the CagriSema decision. Whether that ruling and the expanding semaglutide comorbidity data can sustain the recent recovery will determine if this turnaround story has genuine legs or is merely a pause before another leg down.